Symposium
Session Room: Alsh
Session Room: Alsh
Saturday, June 27, 10:50 AM – 12:05 PM
Symposium 2:
From Mechanisms to Guidelines: Translating Pharmacological Science into Clinical Practice
From Mechanisms to Guidelines: Translating Pharmacological Science into Clinical Practice
The management of psychotic disorders continues to evolve as clinicians and researchers seek to align pharmacological insights with real-world patient care. This symposium will explore novel approaches to antipsychotic selection, the development of gender-specific treatment strategies, and the integration of cardiometabolic health into psychiatric practice. Together, the three talks aim to bridge the gap between mechanistic understanding and patient centered, pragmatic treatment pathways.
The opening presentation, “Pragmatic Precision: Bridging Pharmacological Insights & Patient-Centered Practice” by Dr. Robert McCutcheon, will examine the reclassification of antipsychotics beyond traditional first- and second-generation distinctions. Dr. McCutcheon will highlight emerging pharmacodynamically informed systems that categorize antipsychotics based on receptor profiles and mechanisms of action. He will further discuss the role of digital tools in supporting clinicians to select appropriate treatments, alongside global initiatives to design concise, algorithmic guidelines for schizophrenia pharmacological management. The presentation will emphasize how precision in pharmacology can be translated into clinical pragmatism, balancing evidence-based recommendations with individual patient needs.
The second presentation, “Sex Matters: Guidelines for first choice of antipsychotic in females with first episode psychosis” by Ms. Caroline Hynes, addresses an underexplored area of psychiatric care: the sex-specific considerations in early psychosis treatment. Ms. Hynes will outline the development of clinical practice guidelines that account for the unique pharmacokinetic, pharmacodynamic, hormonal, and psychosocial factors influencing treatment response in females with first-episode psychosis (FEP). She will present data on antipsychotic efficacy, tolerability, and side-effect profiles in women, emphasising reproductive health, metabolic vulnerability, and adherence. This presentation will demonstrate how tailored recommendations along with tools to support implementation can help clinicians provide more equitable and effective care.
The final presentation, “Don’t Go Breaking My Heart: Protecting Cardiometabolic Health in Psychosis” by Dr. Toby Pillinger, will explore the biological underpinnings of cardiovascular disease in individuals with psychotic disorders. Dr. Pillinger will examine how psychosis itself, combined with the metabolic side effects of antipsychotics and antidepressants, contributes to elevated cardiometabolic risk. He will review recent advances in understanding pathophysiological mechanisms, including inflammation, insulin resistance, and autonomic dysfunction. Furthermore, the talk will consider practical strategies for prevention and management, highlighting the importance of integrating psychiatric and physical health care.
Across the three talks, the symposium offers an integrated roadmap: start with mechanism-anchored classification to make better initial choices; ensure those choices are adapted to the specific needs of women with FEP; and embed cardiometabolic protection from day one. Attendees will leave with practical algorithms, digital resources, and monitoring checklists implementable within multidisciplinary pathways. The overarching aim is to combine scientific precision with compassionate, person-centred care, translating complex evidence into decisions that matter to patients and families in routine practice. Discussion time will focus on barriers to adoption, equity, and measuring outcomes that most services value.
The opening presentation, “Pragmatic Precision: Bridging Pharmacological Insights & Patient-Centered Practice” by Dr. Robert McCutcheon, will examine the reclassification of antipsychotics beyond traditional first- and second-generation distinctions. Dr. McCutcheon will highlight emerging pharmacodynamically informed systems that categorize antipsychotics based on receptor profiles and mechanisms of action. He will further discuss the role of digital tools in supporting clinicians to select appropriate treatments, alongside global initiatives to design concise, algorithmic guidelines for schizophrenia pharmacological management. The presentation will emphasize how precision in pharmacology can be translated into clinical pragmatism, balancing evidence-based recommendations with individual patient needs.
The second presentation, “Sex Matters: Guidelines for first choice of antipsychotic in females with first episode psychosis” by Ms. Caroline Hynes, addresses an underexplored area of psychiatric care: the sex-specific considerations in early psychosis treatment. Ms. Hynes will outline the development of clinical practice guidelines that account for the unique pharmacokinetic, pharmacodynamic, hormonal, and psychosocial factors influencing treatment response in females with first-episode psychosis (FEP). She will present data on antipsychotic efficacy, tolerability, and side-effect profiles in women, emphasising reproductive health, metabolic vulnerability, and adherence. This presentation will demonstrate how tailored recommendations along with tools to support implementation can help clinicians provide more equitable and effective care.
The final presentation, “Don’t Go Breaking My Heart: Protecting Cardiometabolic Health in Psychosis” by Dr. Toby Pillinger, will explore the biological underpinnings of cardiovascular disease in individuals with psychotic disorders. Dr. Pillinger will examine how psychosis itself, combined with the metabolic side effects of antipsychotics and antidepressants, contributes to elevated cardiometabolic risk. He will review recent advances in understanding pathophysiological mechanisms, including inflammation, insulin resistance, and autonomic dysfunction. Furthermore, the talk will consider practical strategies for prevention and management, highlighting the importance of integrating psychiatric and physical health care.
Across the three talks, the symposium offers an integrated roadmap: start with mechanism-anchored classification to make better initial choices; ensure those choices are adapted to the specific needs of women with FEP; and embed cardiometabolic protection from day one. Attendees will leave with practical algorithms, digital resources, and monitoring checklists implementable within multidisciplinary pathways. The overarching aim is to combine scientific precision with compassionate, person-centred care, translating complex evidence into decisions that matter to patients and families in routine practice. Discussion time will focus on barriers to adoption, equity, and measuring outcomes that most services value.